Book-to-Bill Ratio Improvement
Fortrea achieved a book-to-bill ratio of 1.23 for the quarter, with a solid pipeline of opportunities for the next two quarters.
Strong Pipeline and Customer Wins
Closed important projects with large pharmaceutical customers and achieved key wins in therapeutic areas such as oncology, diabetes, dermatology, and autoimmune disease.
EBITDA and Revenue in Line with Expectations
EBITDA for the quarter was $64.2 million, a 16.3% increase sequentially, with adjusted EBITDA margin at 9.5%.
Recognition and Awards
Fortrea received external recognition, including being a finalist in the Fierce Healthcare's Excellence in Data-Driven DEI award and the CRO of the Year category in the annual Scrip Awards.
Significant Cash Flow Improvement
Reported $245.7 million in cash flow from operating activities for the first nine months of 2024, compared to $150 million in the prior year.